Recruiting | Phase III
Testing Therapy Sequence for Advanced BRAF Mutation Melanoma
The purpose of this study to compare the good and bad effects of the sequence of immunotherapy followed by BRAF inhibitor therapy if and when it gets worse.
- Group 1: Immunotherapy=Ipilimumab and Nivolumab and at Disease Progression BRAF Inhibitor Therapy=Dabrafenib and Trametinib
- Group 2: BRAF Inhibitor Therapy=Dabrafenib and Trametinib and at Disease Progression Immunotherapy=Ipilimumab and Nivolumab
- Quality of Life surveys
- After completion of the study patients will be followed for 5 years
Key Participation Requirements:
Male or Female
19 years and older
Stage III or IV Melanoma
Patients qualify if melanoma cannot be removed by surgery.
Patients qualify if finished with chemotherapy, immunotherapy, or other therapy by 4 weeks or longer.
Women must not be pregnant or breast feeding.
Methodist Health System Trial Code:
For more information, visit the U.S. National Library of Medicine clinical trial database.
To learn more about this clinical trial please contact us today!